What we do Gujarat Themis Biosyn Ltd manufactures fermentation-based pharmaceutical intermediates and Active Pharmaceutical Ingredients, focusing on Rifamycin products for anti-tuberculosis and digestive tract infections. |
Founded in 1,981 |
Market share Among India's few fermentation-based intermediate manufacturers with strong domestic presence and expanding export footprint to the US and Europe. |
Problem solved Provides high-quality fermentation-based antibiotic intermediates addressing tuberculosis and bacterial infection treatment needs globally. |
Top clients or who we serve Pharmaceutical companies (B2B), domestic and export markets in the United States, Europe, and India. |
Key management - |
Our journey and innovations Incorporated in 1981; pioneered Rifampicin production using fermentation; expanded capacities and launched new API plant in 2025; ongoing R&D for new products. |
Where we operate India (manufacturing and domestic sales), exports to United States and Europe. |
Top products or what we offer Rifamycin S and O intermediates for Rifampicin and Rifaximin drugs; fermentation-based pharmaceutical intermediates and APIs. |
Top brands Rifamycin S: key intermediate, market leader in fermentation-based production; Rifamycin O: important intermediate for Rifaximin synthesis. |
Raw materials needed Fermentation nutrients and synthetic chemical inputs for API production, including raw materials for rifamycin class antibiotics. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue primarily recurring from continuous API and intermediate sales to pharmaceutical manufacturers. |
Our industry position Strong niche player in fermentation-based antibiotic intermediates with expanding API production capabilities. |
Financial highlights FY2025 revenue Rs.150.8 crore; net profit Rs.48.77 crore; stable margins with ongoing investments in capacity and R&D. |
Geographical revenue split Revenue largely from Indian operations with increasing export sales to US and European pharmaceutical markets. |
Order book - |
Whats driving growth Capacity expansions, new API plant commissioning, R&D initiatives, export market growth, and cost optimization. |
Our future plans Expand fermentation and synthetic API capacities, develop new intermediates, and strengthen export market presence. |
Our green promise Implementing hybrid wind-solar power plant to reduce carbon footprint and enhance energy sustainability. |
Our people and values Over 200 employees at Vapi plant; culture emphasizes innovation, sustainability, and compliance. |
Key challenges ahead Market competition, regulatory compliance, scaling new product development, and operational cost management. |
Interesting facts India's first to commercialize fermentation-based Rifampicin; recently listed on NSE in 2025 enhancing investor access. |
Risks and strategy Mitigates risks through technology partnerships, diversification, robust internal controls, and focus on core fermentation business. |
